Previous slide
Next slide
Pioneering
the development and
manufacture of off-the-shelf,
universally implantable,
manufacture of off-the-shelf,
universally implantable,
bioengineered
human tissues
The Humacyte Human Acellular VesselTM (HAVTM)
is a regenerative vascular conduit currently in various stages of clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. We believe our platform technology also has the potential to create solutions for complex organ disease, including bioengineered replacement tissues and organs for coronary artery bypass grafts, pediatric heart sugery, and the treatment of Type 1 diabetes.
Innovation at
commercial scale
Humacyte, Inc. (Nasdaq: HUMA) has developed a disruptive
biotechnology platform to deliver universally implantable, bioengineered
human tissues and organs designed to improve the lives of patients
and transform the practice of medicine. Located in Durham, N.C.,
the company was founded in 2004 by Laura Niklason, MD, Ph.D., a
world leader in tissue engineering and the Chief Executive Officer of
Humacyte, along with Drs. Juliana Blum and Shannon Dahl.
